Establishes certain prescription drug data reporting requirements for hospitals.
Impact
If enacted, A3265 would significantly affect state laws by mandating comprehensive reporting on drug pricing from hospitals. Hospitals will be required to disclose critical data that reflects the minimum and maximum prices paid for drugs, the volume of drugs dispensed, the total rebates and discounts received, as well as net income from these drugs. This data would allow for more informed public and governmental understanding of drug pricing mechanisms and their implications for general healthcare costs.
Summary
Assembly Bill A3265 seeks to establish specific reporting requirements for hospitals regarding prescription drug pricing. This bill expands the existing framework, initially set for pharmacy benefits managers, wholesalers, and manufacturers, to encompass hospitals as entities that must report data to the Division of Consumer Affairs within the Department of Law and Public Safety. The objective is to enable a thorough examination and annual reporting on emerging trends in prescription drug pricing, ultimately improving transparency in the healthcare sector.
Contention
While the bill aims to enhance transparency, potential points of contention may arise regarding the extent of information disclosed and the burdens it could impose on hospitals. Stakeholders may express concerns about the practical implications of compliance, potential costs associated with data collection, and the necessity to protect proprietary information. Additionally, discussions around the balance of hospital fiscal responsibilities and patient care might lead to debates on the bill's effectiveness in improving healthcare affordability without compromising hospital operations.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.